Our Science and Pipeline

Our Science and Pipeline


A healthy immune system eliminates harmful foreign pathogens, while being tolerant of self-tissues and organs. When the immune system malfunctions, cells (T Cells) attack self-tissues and organs, causing autoimmune disease. Current autoimmune disease therapies suppress the immune system, helping to minimize these self-attacks, but also raise susceptibility to harmful foreign pathogens. Immunomodulation, the process in which the immune system reduces self-attacks while properly reacting to fight foreign pathogens, holds great potential for autoimmune disease.

AX-158 Preclinical Evidence in T Cell Driven Autoimmune Diseases

  • Immuno-modulatory: modulates, but does not suppress T cell receptor signaling

  • Suppresses differentiation to Teff cells without suppression of Treg cells

  • In-vivo sustained protective therapeutic effect in an experimental autoimmune encephalomyelitis (EAE) model in multiple sclerosis, during and following treatment

  • Effective in an inflammatory bowel disease (IBD) adoptive transfer model, additional animal models demonstrate efficacy/durable effect (with Artax tool, AX-024)

AX-158

AX-158 is a first-in-class, oral small molecule, preclinical immunomodulating agent in development for the treatment of autoimmune diseases. AX-158 employs a novel mechanism of action that selectively modulates, or adjusts, T cell responses that play a critical role in immune system function. By selectively inhibiting Nck, a protein, AX-158 selectively modulates self-directed T Cell activation which is a cause of autoimmune disease.  Importantly, data suggests that AX-158 is not immunosuppressive and does not impact the immune system’s ability to mount a strong response to foreign pathogens and infections. Further, AX-158’s ability to modulate T cell responses allows the possibility to broadly target several autoimmune diseases, therefore potentially transforming autoimmune disease treatment.

AX-158 Development Plan

development-plan-01

AX-158 Broad Development Potential

Artax AX-158 is designed to immunomodulate T cells. Such T cell immunomodulation holds wide-ranging applicability across a spectrum of autoimmune diseases with high unmet need, and creates broad potential for AX-158 development.

Development Potential-01